8 assets in Thrombocytopenia Due To Immune Destruction

Therapeutic assets addressing Thrombocytopenia Due To Immune Destruction, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Herombopag Thrombocytopenia Due To Immune Destruction	Yin Jie	P3	B (60)
Recombinant Human Thrombopoietin Thrombocytopenia Due To Immune Destruction	Yin Jie	P3	B (60)
Immunoglobulin G1-Lambda2, Anti-(Severe Acute Respiratory Syndrome (Human) Coronavirus 2 (Sars-Cov-2) Spike (S) Glycoprotein, Receptor Binding Domain (Rbd)), Homo Sapiens Monoclonal Antibod Thrombocytopenia Due To Immune Destruction	Imperial College Healthcare NHS Trust	P2	CCC (53)
Ogalvibart Thrombocytopenia Due To Immune Destruction	Imperial College Healthcare NHS Trust	P2	CCC (53)
her2bbζ/cd19t+ t cells Thrombocytopenia Due To Immune Destruction	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	Early P1	C (39)